[HTML][HTML] Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

E Nemes, H Geldenhuys, V Rozot… - … England Journal of …, 2018 - Mass Medical Soc
Abstract Background Recent Mycobacterium tuberculosis infection confers a predisposition
to the development of tuberculosis disease, the leading killer among global infectious …

[HTML][HTML] Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis

H Mulenga, CZ Zauchenberger, EW Bunyasi… - PLoS …, 2020 - journals.plos.org
Introduction Host blood transcriptomic biomarkers have potential as rapid point-of-care
triage, diagnostic, and predictive tests for Tuberculosis disease. We aimed to summarise the …

[HTML][HTML] Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial

TJ Scriba, A Fiore-Gartland… - The Lancet Infectious …, 2021 - thelancet.com
Background Targeted preventive therapy for individuals at highest risk of incident
tuberculosis might impact the epidemic by interrupting transmission. We tested performance …

[HTML][HTML] T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection

M Musvosvi, H Huang, C Wang, Q Xia, V Rozot… - Nature Medicine, 2023 - nature.com
Antigen-specific, MHC-restricted αβ T cells are necessary for protective immunity against
Mycobacterium tuberculosis, but the ability to broadly study these responses has been …

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial

M Tameris, H Mearns, A Penn-Nicholson… - The lancet Respiratory …, 2019 - thelancet.com
Background Infants are a key target population for new tuberculosis vaccines. We assessed
the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine …

Safety and immunogenicity of the adjunct therapeutic vaccine ID93+ GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind …

TA Day, A Penn-Nicholson, AKK Luabeya… - The Lancet …, 2021 - thelancet.com
Background A therapeutic vaccine that prevents recurrent tuberculosis would be a major
advance in the development of shorter treatment regimens. We aimed to assess the safety …

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants

TJ Scriba, M Tameris, N Mansoor, E Smit… - Journal of Infectious …, 2011 - academic.oup.com
Abstract (See the editorial commentary by Dockrell, on pages 1708-9.) Background. BCG,
the only licensed tuberculosis vaccine, affords poor protection against lung tuberculosis in …

A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis–infected Adults

TJ Scriba, M Tameris, E Smit… - American journal of …, 2012 - atsjournals.org
Rationale: Novel tuberculosis (TB) vaccines should be safe and effective in populations
infected with Mycobacterium tuberculosis (M. tb) and/or HIV for effective TB control …

Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents

S Machingaidze, S Verver, H Mulenga… - American journal of …, 2012 - atsjournals.org
Rationale: Conversions and reversions occur with IFN-γ release assay (IGRA) serial testing,
as with the tuberculin skin test (TST). Recent TST conversion is associated with an …

[HTML][HTML] Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy …

SC Mendelsohn, A Fiore-Gartland… - The Lancet Global …, 2021 - thelancet.com
Background A rapid, blood-based triage test that allows targeted investigation for
tuberculosis at the point of care could shorten the time to tuberculosis treatment and reduce …